Both ABP-671 and ABP-745 have the potential to give gout patients more effective and safer alternatives to existing gout therapies.

At exposure levels associated with its clinical dose of 150 mg once daily, GLPG3667 showed inhibition of the IFN-α, and IL-23 pathways, comparable to the expected inhibition for the currently approved ...

The Phase III placebo-controlled, randomised, double-blind study is evaluating ADX-324's efficacy in adults with HAE.

Detailed price information for Pangea Natural Foods Inc. (PNGA-CN) from The Globe and Mail including charting and trades.

The event will take place on November 3, 2025 beginning at 10 am ET and will feature presentations by ProQR Management and ...

The SURPASS study is enrolling patients at research sites across the U.S. and Europe ELA026 targets signal regulatory proteins (SIRP) as a novel approach to treating the life-threatening ...

Medpace Holdings, Inc. is rated Strong Buy with double-digit growth, robust biotech demand, and expanding market share. Click ...

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed at Sun Yat-sen University Cancer Center in the phase I clinical study (Study ID: JSKN022-101) of ...

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine Aggregated TDP-43 is a pathological hallmark of ...

New safety, efficacy and pharmacokinetic results presented from dose escalation portion of the study Anti-tumour activity observed across all dose levels and in various tumour indications  Newcastle, ...

Simulations Plus ( ($SLP) ) has shared an announcement. On October 22, 2025, Simulations Plus announced its preliminary fiscal year 2025 results ...